SpectraCure AB (publ) has decided to seek approval to start a clinical study for primary localised prostate cancer. During autumn, the board and management have evaluated the conditions for approval to start a clinical study from authorities in the USA, Great Britain, Canada and Sweden and assessed these as good. The goal is to start the clinical study in the first half of 2024.

SpectraCure is currently running a clinical study for patients who have recurred prostate cancer after previous radiotherapy. The study is investigating a new method for the treatment of prostate cancer and is conducted using the company's medical technology system, Q-PRO®. The board of SpectraCure has now decided to also seek approval to start a clinical study for primary localised prostate cancer.

Based on the result obtained in the ongoing study, the board assesses the chances as good that the authorities will approve the initiation of a study for primary cancer. The fact that the company already has good and established relationships with hospitals and doctors in North America and Europe, is facilitating the process of getting started with the clinical study for primary localised prostate cancer. The study will be run in parallel with the ongoing study for recurrent prostate cancer.

SpctraCure broadens the recruitment base and addresses a significantly larger market by initiating a clinical study for primary localised prostate cancer. In addition, by running two parallel studies, the risks are reduced since the company obtains independent data sets to confirm the results while achieving redundancy.